GCCL Expands Presence in Asia-Pacific at Asia Bio Partnering Forum 2026

YONGIN, South Korea, Sept. 8, 2026 /CourierPR/ -- Global Clinical Central Lab (GCCL), a South Korean company specializing in clinical trial sample analysis, has strengthened its presence in the Asia-Pacific region by participating as a Platinum Sponsor at the Asia Bio Partnering Forum 2026, held in Singapore from August 31 to September 2.

The forum provided GCCL with a platform to engage with leading pharmaceutical and biotechnology companies, contract research organizations (CROs), and regional stakeholders. Yoo-Hwa Choi, Head of Business Operations at GCCL, highlighted the company's capabilities in clinical sample analysis and its commitment to supporting global drug development during the official ABP 2026 Welcome Reception.

GCCL's participation in the event involved a series of partnering meetings with drug developers working on diverse therapeutic modalities, including mRNA and nucleic acid therapeutics, radiopharmaceuticals, and antibody-based therapies. These discussions focused on the evolving analytical requirements in global clinical development and potential opportunities for collaboration.

The company also met with executives from global CROs and Singapore-based pharmaceutical, diagnostics, and clinical trial service companies. These interactions aimed to explore existing partnerships and identify new opportunities for collaboration. Additionally, GCCL engaged with a Singapore government-affiliated economic development organization to discuss ways to support local biotech companies and strengthen connections within the regional life sciences ecosystem.

At its exhibition booth, GCCL showcased its integrated Central Lab, Bioanalytical Lab, and R&D Lab capabilities, which support clinical development from early through late-stage trials. The company held partnering discussions with pharmaceutical and biotechnology companies and related organizations from Korea, China, Japan, Singapore, Vietnam, and Europe.

"ABP 2026 provided an important opportunity to engage directly with drug developers and global partners across the Asia-Pacific region and better understand their evolving analytical needs across increasingly diverse therapeutic modalities," said Yoo-Hwa Choi.

GCCL's participation in the Asia Bio Partnering Forum 2026 underscores its commitment to expanding its clinical sample analysis and assay development services across the Asia-Pacific region. The company's involvement in the event aligns with its goal of becoming a trusted clinical development partner in Asia-Pacific.